dm+d

327112008

New Medicines

MolgradexAutoimmune (acquired) pulmonary alveolar proteinosis

Information

Molgradex
New molecular entity
Savara
Savara

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

An inhaled formulation of molgramostim, a recombinant human granulocyte macrophage colony stimulating factor (GM-CSF).
PAP is a rare lung disease characterised by the accumulation of lipoproteinaceous material in the alveoli. There are three main forms of PAP, congenital, secondary and acquired. Acquired PAP is the most common type, accounting for about 90% of all cases. Symptoms may include shortness of breath and cough; in severe cases, respiratory failure may occur. The prevalence of PAP in the EU is estimated at 1-9 per 1,000,000 population [1].
Autoimmune (acquired) pulmonary alveolar proteinosis
Inhalation

Evidence based evaluations